Health systems are increasingly talking about the value of technology and AI, but the ability to demonstrate that value financially has not caught up, according to new research from Deloitte that documents a widening healthcare AI ROI gap Deloitte researchers say is becoming more consequential as AI investment scales.
How This Healthcare AI ROI Gap Deloitte Study Was Conducted
The Deloitte Center for Health Solutions surveyed 64 healthcare CFOs and finance leaders and separately analyzed more than 17,000 articles published by health systems and health plans between January 2023 and May 2026. Deloitte’s “2026 U.S. Healthcare CFO Survey” included 32 finance leaders from health systems with more than $1 billion in revenue and 32 from health plans with more than 500,000 members.
What the Article Analysis Revealed
Narratives citing demonstrated value increased from 9% of coverage in 2023 to 19% in 2026. Still, expected value remained the dominant framing, accounting for roughly 35% to 45% of coverage. When organizations did report demonstrated value, it was more often tied to operational or clinical improvements than clear financial outcomes such as cost savings, revenue growth or margin improvement.
The Measurement Maturity Gap Within This Healthcare AI ROI Gap Deloitte Analysis
Forty-four percent of surveyed organizations qualified as “AI scalers,” meaning more than one-third of their generative AI initiatives launched during the previous two years had reached scaled deployment across multiple functions. But among those organizations, just 18% reported mature financial attribution capabilities, meaning they consistently measure AI’s effect on revenue growth or cost savings using defined baselines and clear ownership of key performance indicators. By comparison, 31% of organizations earlier in their AI journeys reported that level of measurement maturity.
Why This Gap Extends Beyond Deloitte’s Research Alone
The challenge extends beyond Deloitte’s research. A separate April report found that while 42% of health systems had deployed AI across multiple use cases, just 4% had achieved scaled implementation with measurable outcomes, reinforcing that this measurement gap is a widely observed industry pattern rather than an isolated finding.
Health Systems Already Closing This Healthcare AI ROI Gap Deloitte Identified
The issue is not necessarily a lack of tangible results. Chicago-based CommonSpirit generated more than $100 million in annual value from AI and robotic process automation in 2025 and now has more than 240 AI applications deployed across the system. Boston Children’s Hospital has reported more than $7 million in redeployed labor savings after reclaiming about 60,000 hours through AI-enabled workflows, with more than one-third of its employees using AI daily.
Mount Sinai’s Structured Approach to Measurement
New York City-based Mount Sinai Health System has gone further in tying AI projects to specific financial targets. The system expects about $50 million in bottom-line impact from its AI portfolio in 2026 and has reported a return exceeding 3-to-1. Mount Sinai evaluates projects against metrics spanning financial impact, patient experience, operational efficiency, quality and safety, illustrating what a genuinely consistent attribution framework can look like in practice.
Why ROI Has Become Multidimensional Within This Healthcare AI ROI Gap Deloitte Framework
That has become an increasingly prominent issue for health system technology leaders. In a recent Becker’s survey of more than 60 healthcare technology, financial, clinical and operational leaders, executives described technology ROI as increasingly multidimensional, extending beyond direct cost savings to measures such as workforce productivity, patient experience, quality and capacity.
Why the Broader Framework Matters More Than Any Single Metric
Given that CommonSpirit, Boston Children’s, and Mount Sinai each measure success differently, ranging from broad annual value figures to reclaimed labor hours to a formal multi-metric scoring system, this variation suggests there may be no single universal ROI framework, but rather a need for each organization to build its own consistent, enterprise-wide measurement discipline.
Why the Stakes Are Rising Within This Healthcare AI ROI Gap Deloitte Warning
The measurement gap could become more consequential as AI moves beyond experimentation. Deloitte found initiatives launched over the previous two years were roughly divided among those that had scaled across multiple functions, those remaining in pilots or limited use and those that had been paused or abandoned. That discipline could become particularly important as health systems face competing demands for capital and greater scrutiny of technology spending.
Deloitte’s Recommendation for Closing This Gap
Deloitte recently urged health systems to become more selective about AI investments, establish clear timelines and performance metrics for pilots, and be willing to scrap initiatives that cannot demonstrate measurable value or scale effectively, a discipline that directly targets the gap between AI enthusiasm and proven financial return this research identifies.
What This Healthcare AI ROI Gap Deloitte Research Means Going Forward
For CFOs, the next phase may therefore be less about whether their organizations are using AI and more about whether they can establish what those investments are producing. Given that CommonSpirit, Boston Children’s, and Mount Sinai have each demonstrated measurable returns are achievable, health systems still struggling to close this gap may find more value in studying these organizations’ specific measurement approaches than in continuing to scale AI deployment without a clear attribution framework in place.
What to Watch Going Forward
As health systems face growing pressure to quantify AI’s financial returns, industry observers will likely watch whether the share of organizations with mature financial attribution capabilities grows beyond the current 18% among AI scalers, and whether more health systems begin scrapping underperforming initiatives as Deloitte has recommended. Given the roughly even three-way split Deloitte found between scaled, still-piloting, and abandoned AI initiatives, this healthcare AI ROI gap Deloitte identified may serve as a defining challenge shaping which health systems successfully translate AI investment into demonstrated value over the next several years.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
